Evogene Schedules Second Quarter 2026 Financial Results Release
Evogene (Nasdaq: EVGN) will release its second quarter 2026 financial results on Tuesday, August 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (Nasdaq: EVGN) will release its second quarter 2026 financial results on Tuesday, August 18, 2026. The company, which focuses on computational chemistry and generative design of small molecules for pharma and agriculture, will hold a management-hosted Zoom conference call that same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results.
Investors must register in advance via the provided Veidan Conferencing link, and a replay of the entire conference will be available on Evogene's website a few days after the event.
Details
News Market Reaction – EVGN
On Jul 30, the day this news came out, EVGN closed 1.60% above the previous close.
Data tracked by StockTitan Argus for the Jul 30 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Zoom conference call scheduled for August 18, 2026, 9:00 AM ET
REHOVOT,

Later that day, company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-second-quarter-2026-financial-results-release-302838854.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.